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Abstract: Monoalkylated derivatives of the unusually polar
all-cis 2,3,4,5,6- pentafluorocyclohexyl (Janus face) motif are
prepared starting from an aryl hydrogenation of 2,3,4,5,6-
pentafluorophenylacetate methyl ester 15. The method used
Zeng’s Rh(CAAC) carbene catalyst 4 in the hydrogenation
following the protocol developed by Glorius. The resultant
Janus pentafluorocyclohexylacetate methyl ester 16 was
converted to the corresponding alcohol 18, aldehyde 13,
bromide 29 and azide 14 through functional group manipu-
lations, and some of these building blocks were used in Ugi-
multicomponent and Cu-catalysed click reactions. NBoc
protected pentafluoroarylphenylalanine methyl ester 35 was
also subject to an aryl hydrogenation, and then deprotection
to generate the Janus face β-pentafluorocyclohexyl-alanine
amino acid 15, which was incorporated into representative
members of an emerging class of candidate antiviral com-
pounds. Log P measurements demonstrate that the all-cis
2,3,4,5,6-pentafluorocyclohexyl ring system is more polar than
a phenyl ring. In overview the paper introduces new building
blocks containing this Janus ring and demonstrates their
progression to molecules typically used in bioactives discov-
ery programmes.
Introduction
Over the last two decades or so organofluorine chemistry has
experienced a ‘Renaissance’, driven by an interest in addressing
the synthesis and properties of products carrying isolated   F or
  CF3 groups, particularly when attached to sp
3 carbons.[1] This is
distinct from an immediately previous era which was defined
by the perfluorocarbons and fluoropolymers industries or within
fine chemicals, with a focus on aryl   F and   CF3 compounds.
[2]
The prospects of novel bioactives (med-chem and agrochem-
icals) resulting from stereogenic fluorine has driven this more
recent agenda, and innovation has been stoked by the intense
international effort and extraordinary growth in new methods
development and catalysis, which defines modern organic
chemistry.[3] Access to this next generation of selectively
fluorinated alkyls has led to a re-evaluation of dogmas such as
‘fluorine increases lipophilicity’. In many cases   F or   CF3
substituted alkyls become more polar (less lipophilic) than the
hydrocarbon and such fluorine effects are being explored in
detail.[4]
We have had a long interest in selective fluorination of alkyl
chains, and particularly in a class of molecules which we have
termed ‘multi vicinal fluoroalkanes’ (Figure 1a) that are defined
by placing a fluorine on each carbon along a chain and with a
defined stereochemistry, to limit isomer mixtures.[5] The pro-
gramme progressed from linear to cyclic alkanes and most
recently we have been exploring the synthesis and properties
of cyclohexanes with multiple vicinal fluorines attached around
the ring with the all-cis stereochemistry.[6–10] The parent
structure, all-cis 1,2,3,4,5,6-hexafluorocyclohexane 1 adopts a
chair conformation resulting in triaxial C  F bonds, and this
arrangement imparts a very high polarity to the ring system as
demonstrated by the extraordinary polar properties of 1 (Fig-
ure 1b). Cyclohexane 1 has a melting point of 208 °C and a
dipole moment of 6.5 D which are particularly high values for
an aliphatic.[6] This has been termed a ‘Janus’ ring system as the
fluorine and hydrogen faces, face in opposite directions and are
responsible for imparting this polarity.[11]
Most recently[10] we have explored monoalkylated structures
of all-cis pentafluorocyclohexane represented by 2a and 2b,
where R is either Me or Et respectively. These systems adopt a
conformation, both in gas phase calculations and in solid state
structures, where the R substituent lies equatorial and there are
three triaxial C  F bonds, rather than the R group axial and with
two diaxial C  F bonds. Therefore against expectation, the
preferred conformation is the more polar for mono alkylated
ring systems. There is a recent and developing interest in
applying this motif to solution state coordination of anions[12]
and for controlled supramolecular assembly of polymers[13] due
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to the self association of the polar rings, however these
derivatives have yet to be explored in a medicinal chemistry
context. In that context the Janus all-cis pentafluorocyclohexyl
ring system is anticipated to have unique properties not
represented by any other substituent in organic chemistry as it
has an electronegative fluorine face and an electropositive
hydrogen face, and both faces have the potential to inter-
act,[8][12] with polar amino acid side chains of opposite electro-
static polarity in protein receptors or enzymes.
Previously[14] we have reported on the preparation of
building blocks for the incorporation of all-cis 2,3,5,6 -
tetrafluorocyclohexane motifs into molecular architectures ap-
propriate to bioactives discovery with illustrative examples
shown in Figure 2. For example amino acid 4 could be
prepared[14d] in various protected forms and the peptoid
product 6[14c] represents a range of products which were
generated through Ugi and Passerini multicomponent
reactions.[15] With such compounds in hand it became apparent
that the fluorine of the 2,3,5,6 - tetrafluorocyclohexane ring
system rendered these compounds significantly more hydro-
philic relative to their aromatic and non-fluorinated cyclohexyl
analogues.[16] This is a striking feature of the ring system as
fluorine is generally considered to impart lipophilicity, however
in these ring systems the fluorine imparts hydrophilicity, as
determined by comparative Log P measurements, illustrated for
the anilines 7–10 in Figure 2. This is due to the polar nature of
the fluorocyclohexane ring with water associating to the protic
face of the Janus rings through hydrogen bonding.[16] In this
paper we now explore the all-cis 1,2,3,4,5-pentafluorocyclohex-
ane ring system in a similar context. Until recently this arrange-
ment of a substituted cyclohexane and with five fluorine around
the ring was not synthetically accessible, however the Glorius
lab have developed[17] a catalytic fluoroaryl hydrogenation
which we have used here to access this class of compounds.
The prototype example shown in Figure 3 demonstrated the
efficient hydrogenation of hexafluorobenzene 11 using Zeng’s
CAAC catalyst 12[18] to generate hexafluorocyclohexane 1, and
the method was extended to prepare a range of all-cis
fluorocyclohexanes and also with different functionalities.[17]
In this paper we report the preparation of a range of
building blocks incorporating the all-cis 2,3,4,5,6-pentafluoro-
cyclohexypentafluoro cyclohexyl motif but with a particular
focus on elaborations of aldehyde 13, azide 14 and amino acid
15 as illustrated in Figure 4.
The utility of aldehyde 13 is explored in Ugi multicompo-
nent reactions,[15] the azide in Cu-catalysed ‘click’ reactions[19]
and the amino acid is incorporated into known coronavirus
inhibitor analogues.[20,21] It emerges as a general phenomenon
that the replacement of cyclohexyl or aryl ring by the all-cis
Figure 1. (a) Acyclic multivicinal fluoroalkane chain, adopts a helical
conformation. (b) Janus face aspect imparts high polarity to cyclohexane 1
and derivatives 2 with all-cis fluorines. (c) Monoalkylated derivatives 2 favour
the more polar triaxial C  F conformation with an equatorial alkyl group.[10]
Figure 2. Previous disclosures on all-cis 2,3,5,6 - tetrafluorocyclohexane
motifs. (a) An amino acid derivative 4;[14d] (b) aldehyde 5 as an Ugi
component. (c). Log P trends across anilines 7–10 indicate increased
hydrophilicity with increased fluorination.[16]
Figure 3. Catalyst and cis-selective hydrogenation of hexafluorobenzene 11
to give 1 as reported by Glorius.[17,18]
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2,3,4,5,6-pentafluorocyclohexyl moiety results in a significant
reduction in Log P values, which suggests that these motifs
would be quite acceptable starting points, for example as
fragments for bioactives and drug discovery programmes.
Results and Discussion
The pentafluoroaryl phenylacetate ester 16 is readily available
and offered a convenient starting point for building block
development. Aryl hydrogenation using the Zeng catalyst 12[17]
and following Glorius protocols[16] resulted in an efficient
conversion to the corresponding cyclohexyl ester 17 as the
major product with the 5-defluorinated co-product 18 as a
minor product (17 :18, 11 : 1). The regiospecific nature of the
defluorination was established by X-ray crystallography of 18
(Scheme 1). This minor co-product could be removed by
chromatography and 17 was progressed to further trans-
formations. Reduction of the ester moiety of 17 to aldehyde 13
was carried out in a two-step protocol as a one-step controlled
reduction with DIBAL did not offer any yield advantage.
Accordingly, ester 17 was reduced to alcohol 19 with DIBAL
and this product was conveniently oxidised to aldehyde 13
after exposure to Dess-Martin periodinane.[22]
1H NMR analysis revealed that aldehyde 13 readily forms a
hemiacetal with [2H4]-methanol suggesting a significant elec-
tron withdrawing effect of the pentafluorocyclohexane ring
system. None- the-less it was a good substrate in a number of
4-component Ugi reactions, of which the products 20–25 are
summarised in Figure 5.
Two of these products (20 and 25) were amenable to X-ray
structure analysis as shown in Figure 6 and this assisted in
confirming their peptoid like structures. In order to elucidate
the effect of the 2,3,4,5,6-all-cis-pentafluorocyclohexane ring on
lipophilicity of this product class, Log P values were determined
for products 20–22 and compared to their corresponding
analogues 26–28 with a phenyl ring in place of the 2,3,4,5,6-all-
cis-pentafluorocyclohexane rings. The Log P values were deter-
mined by HPLC (acetonitrile/water) as described previously[14,16]
and the comparative data are presented in Figure 7. It is clear
that replacement of a phenyl ring by the all-cis 2,3,4,5,6-
pentafluorocyclohexyl moiety increases hydrophilicity, with the
Log P decreasing by 0.4–0.65 Log P units. This trend is consis-
tent with that previously observed for the phenyltetrafluorocy-
clohexyl motifs,[14] and also the all cis-1,2,3-trifluorocyclopropyl
motif,24 and it suggests that this aspect reinforces its utility as a
candidate isostere[25] for hit optimisation studies.
Figure 4. Key building blocks 13–15 carrying the all-cis 2,3,4,5,6-pentafluor-
ocyclohexyl motif used in this study.
Scheme 1. i. 12 (1 mol%), H2 (50 bar), hexane, 4 Å MS, r.t., 16h; ii. DIBAL, THF,
0 °C to r.t, 16h, 83%; iii. Dess-Martin periodinane, THF, r.t, 45min, 85%. X-ray
structure of 17.
Figure 5. General Ugi multicomponent procedure with aldehyde 13 showing
isolated yields and product structures 20–25.
Figure 6. X-ray crystal structures of Ugi multicomponent products 20 and
25.
Figure 7. Comparative Log P values of Ugi fluorocyclohexyl products 20–22
with the corresponding benzyl products 26–28.
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In other functional group interconversions, alcohol 19 was
readily converted to the corresponding bromide 29 by an Appel
reaction,[26] and the bromide to azide 14 as shown in Figure 8a.
Azide 14 is a crystalline solid and the corresponding X-ray is
also shown in Figure 8a. Azide 14 could be readily reduced
under Staudinger conditions[27] to amine 34 to provide another
building block. Azide 14 was also a relatively efficient substrate
in a series of Cu-catalysed ‘click’ reactions[19] with phenyl-
acetylenes to give the products 30–33 as illustrated in Fig-
ure 8b.
A potentially interesting building block of wide utility is
amino acid 15. We report its synthesis here and then its
incorporation into the structural skeleton of a class of antiviral
analogues typified by 34 and 35 in Figure 9. This structural
series of peptidomimetic aldehydes and esters has emerged as
potent inhibitors of the human enterovirus 71(EV-71) and
coronavirus (SARS) protease,[20] and interest in this class of
compounds has received a particular and recent focus as a
starting point to find inhibitors of the COVID-19 coronavirus.[21]
In particular those compounds 34 and 35 containing fluoroaryl-
phenylalanine and cyclohexyl-amino acid show good antiviral
activities.[20] In the context of exploring the all-cis 2,3,4,5,6-
pentafluorocyclohexyl moiety in drug discovery, the two
aldehydes 45 and 48 (Scheme 2) and the two esters 52 and 53
(Scheme 3) of this class of antivirals were prepared carrying the
Janus ring in place of phenyl or cyclohexyl. These syntheses
required amino acid 15 which could be prepared by aryl
hydrogenation of the pentafluoroaryl analogue of fully pro-
tected phenylalanine 36, itself prepared after methylation of
the commercially available NBoc protected L-amino acid.[28]
Hydrogenation using the Glorius/Zeng protocol[16,17] generated
the cyclohexylamino acid 37 in good yield. The pentafluorocy-
clohexyl ring system is susceptible to base decomposition, and
selective ester hydrolysis under acidic conditions proved
difficult, therefore the free amino acid 15 was generated and its
structure confirmed by X-ray analysis (inset in Scheme 2). This
amino acid was then re-protected with the NBoc group to give
38.[29] The synthesis to the target aldehydes 45 and 48 with
either a cinnamate or indole-carboxylate amide could then be
completed following the published[20c] protocols as illustrated in
Scheme 2. Similarly, the corresponding conjugated ethyl ester
analogues 52 and 53, carrying the pendant cinnamate or
indole-carboxylate amides respectively were prepared also from
Figure 8. (a) Reactions forming azide 14, amine 34 and ‘click’ products 30–
33. X-ray structures of triazole 31, azide 14, and amine hydrochloride of 34.
(b) ‘Click’ triazole products 30–33 derived from 14 and an appropriate
phenyl acetylene.
Figure 9. Representatives 34 and 35 of lead Enterovirus-71 and SARS-2
proteases inhibitors.[20] Scheme 2. Synthesis of antiviral candidates 45 and 48 from amino acid 15.
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NBoc protected amino acid 38 following the previous
protocols,[20d] with only minor modifications as illustrated in
Scheme 3. During the Boc deprotection of 50 to get 51 in
methanol, trans esterification of ethyl ester to methyl ester was
observed (1 : 1 mixture) and the reaction of 51 upon reaction
with 42 gave a 1 :1 mixture of 52. Knowing this, the de
protection of Boc for the synthesis of 53 was performed in
ethanol and achieved pure 53.
LogP values were determined[10,16] for products 45, 48, 52
and 53. The values were in the range Log P ~1.5–2.0. These are
low values and in a good range for candidate drug develop-
ment, and they indicate again that the all-cis 2,3,4,5,6-penta-
fluoro-cyclohexyl ring system possesses good properties for
bioactive molecule discovery. In the event the candidate
antivirals 45, 48, 52 and 53 were assessed for their antiviral
activity against Zika virus and the SARS-CoV-2 virus, however
they did not show any activity in these assays.[30]
Conclusion
Several building blocks have been prepared by direct aryl
hydrogenation of all- 2,3,4,5,6-pentafluorophenyl acetaldehyde
16 and the NBoc-protected methyl ester of pentafluoroaryl
phenylalanine. In particular a series of candidate bioactives
were prepared from cyclohexylacetaldehyde 13 and amino acid
15. Aldehyde 13, was used to prepare a range of Ugi
multicomponent products and the amino acid to access direct
analogues of known peptidomimetic aldehydes and esters.
Comparative Log P determinations between phenyl and all-cis
2,3,4,5,6-pentafluorocyclohexyl analogues illustrates an increase
in hydrophilicity for the fluorocyclohexanes and suggests a
utility for this motif in bioactives discovery programmes. These
results should encourage the further exploration of this motif in
medicinal chemistry.
X-ray crystallography
Deposition Number(s) 2098747 (14), 2098748 (15), 2098749
(17), 2098750 (18), 2098751 (19), 2098752 (20), 2098753 (25),
2098754 (31), 2098755 (34HCl), 2098756 (37), 2098757 (53)
contain(s) the supplementary crystallographic data for this
paper. These data are provided free of charge by the joint
Cambridge Crystallographic Data Centre and Fachinformations-
zentrum Karlsruhe Access Structures service.
Acknowledgements
We thank EPSRC for a grant (EP/R013799/1) and Studentships
(JLC) through the EPSRC CRITICAT CDT programme and also the
Chinese Scholarship Council (CY). We also thank Professor
Arvind H Patel at the MRC Centre for Virus Research at the
University of Glasgow for antiviral assays.
Conflict of Interest
The authors declare no conflict of interest.
Keywords: aryl hydrogenation · fluorocyclohexanes · Janus
motif · organic chemistry · organofluorine chemistry
[1] a) S. Meyer, J. Hafliger, R. Gilmour, Chem. Sci. 2021, 12, 10686–10695;
b) R. Hevey, Chem. Eur. J. 2021, 27, 2240–2253; c) I. Ojima (Ed.), ‘Frontiers
of Organic Fluorine Chemistry’, World Scientific Europe, 2020; d) Q. H.
Liu, C. F. Ni, J. B. Hu Hu, Nat. Sci. Rev. 2017, 4, 303–325; e) A. Harsanyi, G.
Sandford, Green Chem. 2015, 17, 2081–2086; f) P. Kirsch, ‘Modern
Fluoroorganic Chemistry. Synthesis, Reactivity, Applications.’ 2nd Edn.,
Wiley-VCH, Weinheim, 2013.
[2] a) R. D. Chambers, ‘Fluorine in Organic Chemistry’ 2nd Edn., Blackwell
Publishing Ltd., Oxford, 2004; b) M. Hudlicky, A. E. Pavlath, ‘Chemistry of
Organofluorine Compounds II,’ ACS Monograph 187, American Chemical
Society, Washington 1995.
[3] a) W. Zhu, X. Zhen, J. Wu, Y. Cheng, J. An, X. Ma, J. Liu, Y. Qin, H. Zhu, J.
Xue, X. Jiang, Nat. Commun. 2021, 12, 3957; b) F. Scheidt, M. Schäfer,
J. C. Sarie, C. G. Daniliuc, J. J. Molloy, R. Gilmour, Angew. Chem. Int. Ed.
2018, 57, 16431–16435; Angew. Chem. 2018, 130, 16669–16673; c) S. M.
Banik, J. W. Medley, E. N. Jacobsen, J. Am. Chem. Soc. 2016, 138, 5000–
5003; d) I. G. Molnar, R. Gilmour, J. Am. Chem. Soc. 2016, 138, 5004–
5007; e) T. D. Beeson, D. W. C. MacMillan, J. Am. Chem. Soc. 2005, 127,
8826–8828; f) L. Hintermann, A. Togni, Angew. Chem. Int. Ed. 2000, 39,
4359–4362; Angew. Chem. 2000, 112, 4530–4533.
[4] a) B. F. J. Jeffries, Z. Wang, H. R. Felstead, J. Y. Le Questel, J. Scott, E.
Chiarparin, J. Graton, B. Linclau, J. Med. Chem. 2020, 63, 1002–1031;
b) Q. A. Huchet, N. Trapp, B. Kuhn, B. Wagner, H. Fischer, N. A.
Kratochwil, E. M. Carreira, K. Müller, J. Fluorine Chem. 2017, 198, 34–46;
c) R. Vorberg, N. Trapp, D. Zimmerli, B. Wagner, H. Fischer, N. A.
Kratochwil, M. Kansy, E. M. Carreira, K. M. Müller, ChemMedChem 2016,
11, 2216–2239; d) H.-J Bôhm, D. Banner, S. Bendels, M. Kansy, B. Kuhn, K.
Müller, U. Obst-Sander, M. Stahl, ChemBioChem. 2004, 5, 637–643.
[5] a) D. O’Hagan, Chem. Eur. J. 2020, 26, 7981–7997; b) N. Al-Maharik, D. B.
Cordes, A. M. Z. Slawin, M. Bühl, D. O’Hagan, Org. Biomol. Chem. 2020,
Scheme 3. Syntheses of antiviral candidates 52 and 53.
Chemistry—A European Journal 
Full Paper
doi.org/10.1002/chem.202102819
5Chem. Eur. J. 2021, 27, 1–7 www.chemeurj.org © 2021 The Authors. Chemistry - A European Journal published by Wiley-VCH GmbH
These are not the final page numbers! ��
Wiley VCH Mittwoch, 06.10.2021
2199 / 221335 [S. 5/7] 1
18, 878–887; c) D. O’Hagan, J. Org. Chem. 2012, 77, 3689–3699; d) L.
Hunter, P. Kirsch, A. M. Z. Slawin, D. O’Hagan, Angew. Chem. Int. Ed.
2009, 48, 5457–5460; Angew. Chem. 2009, 121, 5565–5568.
[6] N. S. Keddie, A. M. Z. Slawin, T. Lebl, D. Philp, D. O’Hagan, Nat. Chem.
2015, 7, 483–488.
[7] R. A. Cormanich, N. Keddie, R. Rittner, D. O’Hagan, M. Bühl, Phys. Chem.
Chem. Phys. 2015, 44, 29475–29478.
[8] B. E. Ziegler, M. Lecours, R. A. Marta, J. Featherstone, E. Fillion, W. S.
Hopkins, V. Steinmetz, N. S. Keddie, D. O’Hagan, T. B. McMahon, J. Am.
Chem. Soc. 2016, 138, 7460–7463.
[9] M. J. Lecours, R. A. Marta, V. Steinmetz, N. Keddie, E. Fillion, D. O’Hagan,
T. B. McMahon, W. S. Hopkins, J. Phys. Chem. Lett. 2017, 8, 109–113.
[10] J. L. Clark, A. Taylor, A. Geddis, R. M. Neyyappadath, B. A. Piscelli, C. Yu,
D. B. Cordes, A. M. Z. Slawin, R. A. Cormanich, S. Guldin, D. O’Hagan,
Chem. Sci. 2021, 12, 9712–9719.
[11] N. Santschi, R. Gilmour, Nat. Chem. 2015, 7, 467–468.
[12] O. Shyshov, K. A. Siewerth, M. von Delius, Chem. Commun. 2018, 54,
4353–4355.
[13] O. Shyshov, S. V. Haridas, L. Pesce, H. Qi, A. Gardin, D. Bochicchio, U.
Kaiser, G. M. Pavan, M. von Delius, Nat. Commun. 2021, 12, 3134.
[14] a) T. Bykova, N. Al-Maharik, A. M. Z. Slawin, M. Bühl, T. Lebl, D. O’ Hagan,
Chem. Eur. J. 2018, 24, 13290–13296; b) T. Bykova, N. Al-Maharik,
A. M. Z. Slawin, D. O’Hagan, Beilstein J. Org. Chem. 2017, 13, 728–733;
c) T. Bykova, N. Al-Maharik, A. M. Z. Slawin, D. O’Hagan, Org. Biomol.
Chem. 2016, 14, 1117–1123; d) M. S. Ayoup, D. B. Cordes, A. M. Z. Slawin,
D. O’Hagan, Org. Biomol. Chem. 2015, 13, 5621–5624; e) M. Salah Ayoup,
D. B. Cordes, A. M. Z. Slawin, D. O’Hagan, Beilstein J. Org. Chem. 2015,
11, 2671–2676; f) A. J. Durie, T. Fujiwara, R. Cormanich, M. Bűhl, A. M. Z.
Slawin, D. O’Hagan, Chem. Eur. J. 2014, 20, 6259–6263.
[15] a) Q. Wang, D.-X. Wang, M.-X. Wang, J. Zhu, Acc. Chem. Res. 2018, 51,
1290–1300; b) I. Ugi, A. Dömling, W. Hörl, Endeavour 1994, 18, 115–122.
[16] A. Rodil, S. Bosisio, M. S. Ayoup, L. Quinn, D. B. Cordes, A. M. Z. Slawin,
C. D. Murphy, J. Michel, D. O’Hagan, Chem. Sci. 2018, 9, 3023–3028.
[17] a) Z. Nairoukh, M. Wollenburg, C. Schlepphorst, K. Bergander, F. Glorius,
Nat. Chem. 2019, 11, 264–270; b) M. P. Wiesenfeldt, T. Knecht, C.
Schlepphorst, F. Glorius, Angew. Chem. Int. Ed. 2018, 57, 8297–8300;
Angew. Chem. 2018, 130, 8429–8432; c) M. P. Wiesenfeldt, Z. Nairoukh,
W. Li, F. Glorius, Science 2017, 357, 908–912.
[18] a) X. Zhang, L. Ling, M. Luo, X. Zeng, Angew. Chem. Int. Ed. 2019, 58,
16785–16789; Angew. Chem. 2019, 131, 16941–16945; b) Y. Wei, B. Rao,
X. Cong, X. Zeng, J. Am. Chem. Soc. 2015, 137, 9250–9253.
[19] a)
C. W. Tornøe, C. Christensen, M. Meldal, J. Org. Chem. 2002, 67, 3057–
3064; b) V. V. Rostovtsev, L. G. Green, V. V. Fokin, K. B. Sharpless, Angew.
Chem. Int. Ed. 2002, 41, 2596–2599; Angew. Chem. 2002, 114, 2708–
2711.
[20] a) W. Dai, D. Jochmans, H. Xie, H. Yang, J. Li, H. Su, D. Chang, J. Wang, J.
Peng, L. Zhu, Y. Nian, R. Hilgenfeld, H. Jiang, K. Chen, L. Zhang, Y. Xu, J.
Neyts, H. Liu, J. Med. Chem. 2021, 64, https://doi.org/10.1021/acs.jmed-
chem.0c02258; b) W. Dai, B. Zhang, X.-M. Jiang, H. Su, J. Li, Y. Zhao, X.
Xie, Z. Jin, J. Peng, F. Liu, C. Li, Y. Li, F. Bai, H. Wang, X. Cheng, X. Cen, S.
Hu, X. Yang, J. Wang, X. Liu, G. Xiao, H. Jiang, Z. Rao, L.-K. Zhang, Y. Xu,
H. Yang, H. Liu, Science 2020, 363, 1331–1335; c) Y. Zhai, X. Zhao, Z. Cui,
M. Wang, Y. Wang, L. Li, Q. Sun, X. Yang, D. Zeng, Y. Liu, Y. Sun, Z. Lou,
L. Shang, Z. Yin, J. Med. Chem. 2015, 58, 9414–9420; d) C.-J. Kuo, J.-J.
Shie, J.-M. Fang, G.-R. Yen, J. T. A. Hsu, H.-G. Liu, S.-N. Tseng, S.-C. Chang,
C.-Y. Lee, S.-R. Shih, P.-H. Liang, Bioorg. Med. Chem. 2008, 16, 7388–
7398; e) K. Anand, J. Ziebuhr, P. Wadhwani, J. R. Mesters, R. Hilgenfeld,
Science 2003, 300, 1763–1767.
[21] a) R. L. Hoffman, R. S. Kania, M. A. Brothers, J. F. Davies, R. A. Ferre, K. S.
Gajiwala, M. He, R. J. Hogan, K. Kozminski, L. Y. Li, J. W. Lockner, J. Lou,
M. T. Marra, L. J. Mitchell, B. W. Murray, J. A. Nieman, S. Noell, S. P.
Planken, T. Rowe, K. Ryan, G. J. Smith, J. E. Solowiej, C. M. Steppan, B.
Taggart, J. Med. Chem. 2020, 63, 12725–12747; b) L. Zhang, D. Lin, Y.
Kusov, Y. Nian, Q. Ma, J. Wang, A. von Brunn, P. Leyssen, K. Lanko, J.
Neyts, A. de Wilde, E. J. Snijder, H. Liu, R. Hilgenfeld, J. Med. Chem. 2020,
63, 4562–4578.
[22] D. B. Dess, J. C. Martin, J. Org. Chem. 1983, 48, 4155–4156.
[23] a) C. Giaginis, A. Tsantili-Kakoulidou, J. Liq. Chromatogr. Relat. Technol.
2008, 31, 79–96; b) C. M. Du, K. Valko, C. Bevan, D. Reynolds, M. H.
Abraham, Anal. Chem. 1998, 70, 4228–4234.
[24] Z. Fang, D. B. Cordes, A. M. Z. Slawin, D. O’Hagan, Chem. Commun. 2019,
55, 10539–10542.
[25] a) B. M. Johnson, Y. Z. Shu, X. L. Zhuo, N. A. Meanwell, J. Med. Chem.
2020, 63, 6315–6386; b) H. Mei, J. Han, S. White, D. J. Graham, K. Izawa,
T. Sato, S. Fustero, N. A. Meanwell, V. A. Soloshonok, Chem. Eur. J. 2020,
26, 11349–11390; c) E. P. Gillis, K. J. Eastman, M. D. Hill, D. J. Donnelly,
N. A. Meanwell, J. Med. Chem. 2015, 58, 8315–8359.
[26] R. Appel, Angew. Chem. Int. Ed. 1975, 14, 801–811; Angew. Chem. 1975,
87, 863–874.
[27] Y. G. Gololobov, L. F. Kasukhin, Tetrahedron 1992, 48, 1353–1406.
[28] P. P. Geurink, N. Liu, M. P. Spaans, S. L. Downey, A. M. C. H.
van den Nieuwendijk, G. A. van der Marel, A. F. Kisselev, B. I. Florea, H. S.
Overkleeft, J. Med. Chem. 2010, 53, 2319–2323; N-Boc-L-
(pentafluoroaryl)phenylalanine - Fluorochem. Ltd., Catalogue No
008086; CAS Number 34702–60-8.
[29] E. Vaz, M. Fernandez-Saurez, L. Muñoz, Tetrahedron: Asymmetry 2003,
14, 1935–1942.
[30] Antiviral assays were conducted the MRC-Centre for Virus Research at
the University of Glasgow, UK.
Manuscript received: August 3, 2021
Accepted manuscript online: September 6, 2021
Version of record online: ■■■, ■■■■
Chemistry—A European Journal 
Full Paper
doi.org/10.1002/chem.202102819
6Chem. Eur. J. 2021, 27, 1–7 www.chemeurj.org © 2021 The Authors. Chemistry - A European Journal published by Wiley-VCH GmbH
These are not the final page numbers! ��
Wiley VCH Mittwoch, 06.10.2021
2199 / 221335 [S. 6/7] 1
FULL PAPER
Janus all-cis 2,3,4,5,6-pentafluorocy-
clohexyl building blocks have been in-
corporated into medicinal chemistry
type products. These cyclohexanes
have polarized faces and represent a
unique motif for medicinal chemistry.
The paper introduces a range of new
accessible building blocks which can
be elaborated into a diversity of drug
type structures demonstrating their
wider utility for exploration in bioac-
tives discovery chemistry.
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